Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections... Show more
MRK is expected to report earnings to rise 24.42% to $2.14 per share on April 24
Q1'25
Est.
$2.14
Q4'24
Missed
by $0.09
Q3'24
Beat
by $0.07
Q2'24
Beat
by $0.12
Q1'24
Beat
by $0.14
The last earnings report on February 04 showed earnings per share of $1.72, missing the estimate of $1.81. With 21.42M shares outstanding, the current market capitalization sits at 331.75B.